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Background & Objective: Acute lymphoblastic leukemia (ALL) is a malignant 
disease that arises from various mutations in B or T-lymphoid progenitors. MicroRNAs 
(miRNAs) regulate gene expression by binding to the 3' untranslated region of protein-
coding genes. Dysregulation of miRNA expression may result in the development of 
cancerous phenotypes. Therefore, for the first time in this field, the present study aims 
to investigate the effect of overexpression of miR-506 in Jurkat (acute T cell leukemia) 
cell line. 
Methods: In this study, Jurkat cell lines were cultured in RPMI-1640 medium. Next, miR-506 
was transfected with concentrations of 50 and 100 nM with Lipofectamine 2000. The accuracy 
of the transfection was confirmed by the transfection of siRNA conjugated with FITC. 48 h 
after transfection, the cells were prepared for other tests (flow cytometry, MTT assay, and RNA 
extraction). The expression level of miR-506 in the cells was analyzed using the quantitative 
real-time reverse transcription polymerase chain reaction (qRT-PCR). Finally, SPSS 21 
software was used for the data analysis. 
Results: According to our results, the viability of cells in concentrations of 50 and 100 
nM was significantly higher than the control group. By overexpression of miR-506, the 
expressions of pro-apoptotic genes (p53, p21) and anti-apoptotic gene B-cell 
lymphoma-2 (BCL-2) are decreased and increased, respectively. 
Conclusion: This study showed that miR-506 may function as an oncogenic miRNA in the 
T- ALL cell line. In conclusion, overexpression of miR-506 leads to an increase in viable 
cancer cells. 
Main Subjects:  
Hematopathology  
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Introduction
Acute lymphoblastic leukemia (ALL) is a malignant 
disease that arises from various genetic mutations in B 
or T-lymphoid progenitors, leading to blast cell 
proliferation, and accumulation of leukemic cells in 
bone marrow (1). T-cell ALL (T-ALL) is a subtype of 
ALL based on immunophenotype. It accounts for ~12% 
and ~25% of cases of ALL in children and adult patients, 
respectively (2). In general, patients with T-ALL have a 
poorer prognosis than other ALL patients, including 
~15% and ~50% of pediatric and adult cases 
respectively, which indicates resistance to treatment or 
the risk of experiencing relapse (2, 3). Therefore, in 
order to improve the prognosis of patients with ALL and 
increase the efficacy of current treatments while 
reducing their side effects, identification of the 
molecular mechanisms is vital (4). 
 Finding new therapeutic targets like microRNAs 
(miRNAs) is appealing and worth investigating. MiRNAs 
are 18–25 nucleotide, single-stranded non-coding RNAs 
that mediate the expression of various genes (5, 6). They 
regulate gene expression by binding directly to the 3' 
untranslated region (3'UTR) of protein-coding genes (7, 
8). It is estimated that approximately 50% of all protein-
coding genes are regulated by miRNAs. Also, these small 
molecules play critical roles in different types of 
biological cell processes, including cell proliferation and 
differentiation, organ development, apoptosis, and 
metabolism (9). 
However, some miRNAs act as oncogenes in cancers 
by negatively regulating tumor suppressor genes (10). 
Among these targets, the tumor suppressor genes p53 and 
p21 are particularly important, since they can be a direct 
target of miRNAs and regulate the expression and 
processing of them (11, 12). It has been shown that these 
tumor suppressors can be inactivated by miRNAs 
overexpression in malignancies and may result in the 
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development of cancerous phenotypes (12, 13). 
Therefore, it is important to identify dysregulated 
miRNAs and their targets for the detection of cancers and 
finding new therapeutic strategies (10). 
In T-ALL like other cancers miRNAs can be 
dysregulated (14). Sayadi et al. showed that the 
overexpression of miR-192 in ALL patients upregulated 
tumor suppressor gene p53 and downregulated 
prosurvival gene BCL2, which in turn induced apoptosis 
(15). Mavrakis et al.  identified five miRNAs (miR-19b, 
miR-20a, miR-26a, miR-92, and miR-223) that could 
promote  T-ALL development in a mouse model. They 
found that these miRNAs increased the pathogenesis of T-
ALL by targeting tumor suppressor genes (16). Moreover, 
in another study, it was shown that four miRNAs (miR-
101, miR-140-5p, miR-448, and miR-485-5p) were 
downregulated in T-ALL patient specimens and cell lines 
(17). However, for better diagnosis and treatment of T-
ALL patients, other leukemic oncogenic miRNAs are 
required to be identified. 
MiR-506 is considered as a component of an X 
chromosome-linked miRNA cluster in the primate testis 
(18, 19). Depending on the tumor types, miR-506 has 
reportedly functioned as a tumor-suppressive or an 
oncogenic miRNA (20). Moreover, previous studies have 
focused on the role of miR-506 in solid tumors like 
ovarian cancer (21), pancreatic cancer (22) and cervical 
cancer (18). However, the biological function of miR-506 
in T-ALL cells remains unclear. 
This study aimed to investigate the effects of miR-506 
on the proliferation and viability of the T-ALL cell line 
(Jurkat). In addition, to examine the molecular 
mechanism of miR-506, the effect of this miRNA on p53 
pathway genes like p21, p53, and prosurvival B-cell 
lymphoma-2 (BCL-2) has been investigated by 
quantitative real-time polymerase chain reaction (qRT-
PCR). 
 
    Materials and Methods 
Cell Line and Cell Culture 
The human T-ALL cell line Jurkat was obtained from 
the Iranian Stem Cell Technology Research Center 
(Tehran, Iran), and cultured in RPMI-1640 medium with 
L-glutamine (Cell Biotechnology Saba Arna, Fars, Iran), 
with 10% fetal bovine serum (FBS) (Gibco, USA), 100 
U/mL penicillin and 100 mg/mL streptomycin. Then, the 
cell was incubated at 37°C under a humidified atmosphere 
consisting of 95% air and 5% CO2. Finally, suspension-
cultured cells were used for transfection at 80% 
confluence (6). 
Transfection  
The Jurkat cell lines were divided into control group, 
scramble group, as well as two treated groups that were 
transfected by 50 and 100 nM of miR-506 (Eurofins 
Genomics Germany). The sequence of the mature miR-
506 was as follows: (5'-
UAAGGCACCCUUCUGAGUAGA-3').  For Jurkat 
cells transfection, Lipofectamine 2000 (Invitrogen, USA) 
was used according to the manufacturer’s manual. Briefly, 
firstly, one day before the transfection, Jurkat cells were 
seeded in 24-well plates at a concentration of 2×105 
cells/well in a medium with serum but without antibiotics. 
Secondly, 50 and 100 nM miR-506 were diluted in 50 μL 
OptiMEM in two tubes (Gibco, USA). Thirdly, in two 
other tubes, 1.5 μL Lipofectamine was diluted in 50 μL 
OptiMEM in each. After 5 min of incubation, the diluted 
miR-506 from stage 2 was combined with the diluted 
Lipofectamine from stage 3. Then, the compound was 
incubated at room temperature for 20 min. Finally, it was 
added directly to each well-containing cells (from stage 1) 
and was mixed gently. Non-transfected Jurkat cell line 
was considered as the control group. siRNA conjugated 
with FITC (Santa Cruz Biotechnology, Inc, Texas, USA) 
was utilized as a scramble and transfected at a final 
concentration of 50 nM in a similar manner. Transfection 
efficiency was detected by scramble and qRT-PCR.  
 
MTT Assay 
The day after transfection, fresh RPMI containing 
10% FBS replaced the culture medium. The culture plates 
were incubated at 37°C for the following day in a 
humidified atmosphere containing 5% CO2. Then, 10 μL 
3-[4, 5-dimethylthiazol-2-yl]-2, 5 diphenyl tetrazolium 
bromide (MTT) solution (5 mg/mL) was added to each 
well and the plates were incubated for a further 4 h. After 
removal of the medium, dimethyl sulfoxide (DMSO) was 
added to each well (23). The culture plates were shaken 
for 15 min and the absorption was measured at the 
wavelength of 570 nm by an enzyme-labeled analyzer. 
Three independent experiments were performed.  
 
Flow Cytometry Analysis 
Cell apoptosis was evaluated using an Annexin V-
FITC Apoptosis Detection kit with 7-AAD (BioLegend, 
San Diego, CA, USA) (48 h after transfection) according 
to the following manufacturer’s manual (24): First, cells 
were washed with cold BioLegend's cell staining buffer 
and were resuspended in binding buffer. Subsequently, 
cells were incubated with 5 μL Annexin V/FITC and 5 μL 
7-AAD for 15 min at room temperature in the dark. Then, 
400 µL of Annexin V binding buffer was added to each 
tube of the cell. A flow cytometer (BD Biosciences) was 
used to detect apoptosis in Jurkat cells. Three independent 
experiments were performed.  
RNA Extraction and Quantitative Real-Time 
Reverse Transcription Polymerase Chain Reaction 
(qRT-PCR)    
Total RNA was extracted from cultured cells in the 
different groups by the Total RNA Isolation Kit (Santa 
Cruz Biotechnology, Inc., Texas, USA), according to the 
manufacturer’s instruction, 48 h after the transfection. 
Nanodrop spectrophotometer (Thermo Fisher Scientific, 
Inc.) and electrophoresis on 2% agarose gel were used to 
determine RNA concentration after extraction (25). 
According to the manufacturer's instructions, cDNA of 
miRNA and other genes were generated using a highly 
sensitive cDNA Synthesis kit (Bonbiotech, Inc, Iran) and 
H Minus First Strand cDNA Synthesis Revert Aid kit 
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(Thermo Fisher Scientifc, Inc., USA) respectively. 
Specific primers for PCR amplification were synthesized 
by Bonbiotech Company (Bonbiotech, Inc, Iran) as 
represented in Table 1. 
 The expression level of miR-506 and mRNA in the 
cells were evaluated on the Step One Plus Real-Time PCR 
systems (ABI, US). Expression of p53, p21, and BCL-2 
mRNA in Jurkat cells were quantified using a 2X Real 
MOD Green PCR Master Mix kit (Takara Bio, Inc., Otsu, 
Japan), according to the manufacturer's instructions. 
Briefly, 2 µL cDNA product was diluted in a final volume 
of 20 µL, containing 10 pmol of each primer, 10 µL 2× 
reaction mixture of SYBR Green and 7.4 µL sterile 
deionized water (12). The cycling program was as 
follows: An initial denaturation step at 95°C for 10 min, 
followed by 40 cycles including a denaturation step at 
95°C for 10 sec, annealing and extension at 55°C for 40 
sec. Hypoxanthine-guanine phosphoribosyl transferase 
(HGPRT) and U6 snRNA were selected as internal 
housekeeping controls. All PCRs were performed in 
triplicate. The relative expression levels of miR-506 and 
p53, p21, and BCL-2 mRNA were calculated by the 2-ΔΔCT 
method (26). 
Statistical Analysis 
All statistical analyses were performed using SPSS 
21.0 software (SPSS, Inc., Chicago, IL, USA). The data 
are presented as the mean ± standard deviation (SD) from 
at least three independent experiments. In order to make a 
general comparison of the difference between treated cell 
groups and the control group, the Kruskal-Wallis test was 
utilized. The difference among the groups (two by two) 
was analyzed by the Mann-Whitney test. P-value<0.05 
was considered to indicate a statistically significant 
difference. 
 
     Results 
Accuracy of Transfection 
Following the transfection (Six hours), the scramble 
group (absorbance: 490 nm, emission: 514 nm) was 
examined by the green filter of the fluorescent 
microscope. Observing inside the cells through the green 
light of the fluorescent, the accuracy of transfection was 
confirmed (Figure 1).
 
Table 1. Sequence of Real Time PCR primers 
Primer Sequence Direction Gene 
5'- TAAGGCACCCTTCTGAGTAGA -3' F MicroRNA-506 
5'- GCGAGCACAGAATTAATACGAC -3' R  
5'-CTCGCTTCGGCAGCACATATAC-3' F U6 small nuclear RNA 
5'-ACGCTTCACGAATTTGCGTGTC-3' R  
5'-TAACAGTTCCTGCATGGGCGGC-3' F p53 
5'-AGGACAGGCACAAACACGCACC-3' R  
5'-GAGGCCGGGATGAGTTGGGAGGAG-3' F p21 
5'-CAGCCGGCGTTTGGAGTGGTAGAA-3' R  
5'-GGTGGGGTCATGTGTGTGG-3' F BCL-2 
5'-CGGTTCAGGTACTCAGTCATCC-3' R  
5'-GGACAGGACTGAACGTCTTG-3' F HGPRT 
5'-ATAGCCCCCCTTGAGCACAC-3 R  
HGPRT, Hypoxanthine-guanine phosphoribosyl transferase; BCL-2, B-cell lymphoma 2; 
F, forward; R, reverse 
 
 
Fig. 1. Green light of FITC attached to siRNA in the scramble sample. It indicates the correctness of the Transfection. A (10x 
magnification), B (40x magnification).  
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MiR-506 Increased the Viability of Jurkat Cells 
Using MTT assays, we attempted to determine 
whether the viability of Jurkat cells was affected by 
miR-506. Our data indicated that the viability of Jurkat 
cells increased in comparison with the control group 
when the cells were transfected with 50 and 100 nM of 
miR-506 ) P=0.037, 0.037, respectively). Moreover, the 
viability of cells transfected with 100 nM of miR-506 
increased in comparison with 50 nM group, but the 
difference was insignificant (P=0.37) and survival of 
the scramble group was not significantly different from 
the control group (P=0.48(. The viability mean of the 
studied groups with triple repetition is represented in 
Table 2 and Figure 2.
 
Table 2. Viability of Jurkat cells by MTT method (%) 
Treated  Non treated 
100nM 50nM Scramble 
119±3.0 117  ±3.7 97±4.5 
 
 
Fig. 2: Viability of treated and non-treated groups with miR-506 based on MTT test (%).*P<0.05 
 
MiR-506 Decreased Apoptosis in Jurkat Cell 
For cell apoptosis assay, the treated and non-treated 
Jurkat cells were stained with Annexin V-FITC and 7-
AAD and were analyzed by the flow cytometry. The 
position of viable, apoptotic, and necrotic cells in the 
flow cytometry quadrant (according to the type of 
absorbent stains) is illustrated in Table 3. The result 
showed that increasing miR-506 significantly inhibited 
the apoptosis of Jurkat cells. In other words, increasing 
the overexpression of miR-506 in transfected groups (50 
and 100 nM) led to higher cell viability, compared to the 
control group (91%, 93.2%, 79.5%, respectively, as 
shown in Figures 3 and 4). 
 
Table 3. The position of viable, apoptotic and necrotic cells in the flow cytometry quadrant according to the type of absorbent stain 
7-AAD Annexin-V stain 
  Cell Condition 
Neg Neg Viable (Q1) 
Neg Pos Early Apoptotic (Q2) 
Pos Pos Late Apoptotic (Q3) 
Pos Neg Necrotic (Q4) 
  Pos; Positive, Neg; Negative 
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Fig. 3. Flow cytometric results of treated and nontreated cell groups. A. Control group, 
B. Scramble, C. treated with 50 nM of miR-506, D. treated with 100 nM of miR-506 
  
 
Fig. 4. Viable cell Q1 in treated and non-treated groups (%). In transfected cells with miR-506, 
the viable cells increased significantly compared with the control group and the scramble. *P<0.05 
 
The viable cells were significantly different in the 
treated group (50 and 100 nM) compared with the control 
group (P= 0.034, 0.022), but there was no significant 
difference between the treated groups (50 and 100 nM) 
(P=0.37). According to Figure 5, total apoptotic cells 
(early apoptotic plus late apoptotic) in the treated group 
(50 and 100 nm) were significantly different compared 
with control (P= 0.046, 0.038 respectively), while total 
apoptotic cells in treated groups (50 and 100 nm) didn’t 
show a significant difference in comparison with each 
other (P=0.37). Also, the percentage of necrotic cells in 
treated groups (50 and 100 nM) compared with the control 
group and also between the two treated groups were not 
significantly different (P= 0.09, 0.07, 0.08, respectively). 
Overexpression of miR-506 in Treated Groups 
For higher confirmation of the transfection of miR-
506 in Jurkat cell, the expression of miR-506 was 
measured via qRT-PCR. As shown in Figure 6, the 
miR-506 expression in the control group was 
significantly different compared with 50 and 100 nM 
groups (P= 0.037, 0.037, respectively). In other words, 
in 50 nM and 100 nM groups, a fold change of 3.9 and 
10.2 was observed, respectively, indicating a 
significant difference between 50 nM and 100 nM 
groups (P=0.04). 
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Fig. 5: Percentage of primary, late apoptotic and necrotic cells in Q2, Q3, Q4. By increasing the transfection of miR-506, the total 
apoptotic cells decreased significantly compared to the control group and the scramble *P<0.05. 
 
 
Fig. 6. The expression of miR-506 in treated and non-treated cell groups. *P<0.05 
 
P53 Gene Expression Reduced in Cells 
Transfected with miR-506 
To further understand the role of miR-506 in the 
apoptosis of Jurkat cells, the expression of p53 as a 
regulatory gene of apoptosis was assessed by qRT-PCR. 
As represented in Table 4 and Figure 7, p53 gene 
expression in groups transfected with miR-506, 
significantly downregulated (fold change of 0.63, 0.34 
in 50 and 100 nM, respectively) compared with the 
control (P=0.037, 0.037). Moreover, the gene expression 
in the 50 nM group was remarkably higher than the 100 
nM group (P=0.04). It was found that p53 gene 
expression decreased following overexpression of 
miR-506  
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P21 Gene Expression Reduced in Cells 
Transfected with miR-506  
The relation between p21 expression and 
overexpression of miR-506 in two 50 and 100 nM 
concentrations in Jurkat cells, was assessed by qRT-
PCR. As shown in Figure 7 and Table 4, p21 gene 
expression in groups transfected with miR-506 was 
significantly downregulated compared  with the control 
group (fold change in 50 and 100 nM: 0.90, 0.87, 
respectively; P=0.037 in each). No significant 
difference was shown between 50 and 100 nM groups 
(P=0.09). 
BCL-2 gene expression increased following 
overexpression of miR-506  
In order to evaluate whether miR-506 regulated 
BCL2, 48 h after transfection in Jurkat cells, BCL2 
mRNA levels were measured via qRT-PCR. BCL-2 
expression significantly increased in the treated group 
(50 and 100 nM) compared with the control (P= 0.034, 
0.038). As demonstrated in Table 4 and Figure 7, BCL-
2 gene expression increased after enhancing the dose of 
miR-506 (fold change in 50 and 100 nM: 1.51, 1.64, 
respectively). However, no significant difference was 
shown between the treated groups (P=0.06).
 
Table 4. Expression of miR-506, pro-apoptotic genes and anti-apoptotic genes in cell groups 
Gene miR-506 p53 p21 BCL-2 
GROUP     
Sramble 1.09±0.100 1.20±0.090 1.06±0.050 1.02±0.060 
50 nM 3.90±0.006 0.63±0.020 0.73±0.010 1.51±0.150 
100 nM 10.20±0.900 0.34±0.010 0.70±0.015 1.64±0.190 
Data are presented as the mean of fold changes ± standard deviation. BCL-2, B-cell lymphoma  
2; miR, microRNA 
 
 
Fig. 7. Expression of pro-apoptotic and anti-apoptotic genes in treated and non-treated cell groups *P<0.05 
 
     Discussion 
Many studies have shown that dysregulation of 
miRNAs expression can lead to tumor progression and 
initiation. Therefore, the identification of dysregulated 
miRNAs in the pathogenesis of malignancy may help in 
finding more effective cancer therapy (4). Recently, the 
aberrant expression of miR-506 in different types of 
malignancies has been identified. For example, Banales 
et al. found that miR-506 upregulated in cholangiocytes 
of patients with Primary Biliary Cirrhosis which led to 
impaired function of Cl−/HCO3−anion exchanger 2 
(AE2) and an increase in Primary Biliary Cirrhosis (27). 
Streicher et al. demonstrated that the miR-506-514 
cluster was significantly overexpressed in melanoma 
tissue and promoted melanoma growth (28). In addition, 
Ananthanarayanan et al. discovered that miR-506 
downregulated InsP3R3 expression and impaired Ca2+ 
signaling and secretion in duct cells (cholangiocytes) 
thus, inhibited fluid secretion (29). In contrast, this 
miRNA acts as a tumor suppressor in colorectal, breast, 
and ovarian cancers, and inhibits tumor proliferation (21, 
30, 31). In general, weather this miRNA functions as an 
oncogene or a tumor suppressor seems to be dependent 
on the cell type (32). However, the role of miR-506 in 
T-ALL progression remains unknown. 
In the present study, to further investigate the effects 
of miR-506 on T-ALL, Jurkat cells were transfected 
with miR-506, which induced an increase in the 
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expression of miR-506. The overexpression of miR-506 
could enhance the viability of Jurkat cells and decrease 
their apoptosis rate. These findings suggest that miR-506 
may have an oncogenic role in Jurkat cells.  
In previous studies, it has been demonstrated that 
miR-506 might regulate different genes associated with 
various malignancy progressions, including YAP, 
ROCK1, CDK4/6-FOXM, IQGAP1 and SPHK1 (33). 
Moreover, another gene regulated by miR-506 is p53 
suppressor tumor, which plays a critical role in cancers. 
Song et al. reported that miR-506 was consistently 
overexpressed in retinoblastoma cells and tumor 
specimens. In addition, they showed that inhibition of 
miR-506 led to the upregulation of both p53 and Bax 
and induced suppression of cell viability (33). In 
contrast, in another study, it was shown that Ectopic 
expression of miR-506 inhibited the NF-κB pathway 
and increased ROS generation, which in turn activated 
p53 to suppress lung cancer cell viability (34).  
p53 is a tumor suppressor/transcription factor that 
regulates various cell functions in humans and other high 
eukaryotes (35). In reaction to diverse stressors, p53 
transactivates many downstream genes, such as p21 and 
PUMA. The interaction between p53 and p21 creates the 
p53/p21 complex, which binds to prosurvival BCL-2 
family proteins to liberate pro-apoptotic groups such as 
Bax and Bak, consequently promoting apoptosis or 
cycle arrest (13, 36). In many cancers, the functions of 
p53 pathway components, such as p21 and p53, have 
been disrupted. On the other hand, many studies have 
shown that miRNAs may target components of this 
pathway and potentially inhibit their expression, thereby 
increasing malignancies (13, 35). Moreover, BCL-2 acts 
as an apoptosis regulator and has been shown to play a 
critical role in the pathogenesis of various types of 
cancer (12).  
Lv et al. demonstrated that overexpression of miR-
149 significantly inhibited chondrocyte apoptosis by 
decreasing the protein levels of Bax and p53 and 
increasing the levels of BCL-2 (37). It has also been 
shown that miR-34a plays an anti-tumor role in human 
esophageal squamous cancer cells and inhibits cellular 
growth by downregulation of Sirtuin1 (SIRT1) and 
upregulation of p53/p21 (38). However, the effect of 
miR-506 on the components of the p53 pathway in T-
ALL has not been investigated yet.  
In the present study, the results of qRT-PCR assay 
indicated that overexpression of miR-506 in Jurkat cells 
resulted in an increase in the levels of prosurvival BCL-
2 mRNA. In addition, mechanistic investigations 
determined that miR-506 may enhance the viability of 
Jurkat cells partially by regulating and increasing the 
level of BCL-2. Moreover, this study has demonstrated 
that miR-506 overexpression is inversely correlated with 
lower p53 and p21 mRNA levels in Jurkat cells. 
Therefore, overexpression of miR-506 was associated 
with a decrease in the expression of p53 and p21 genes, 
which could lead to apoptosis reduction. Overall, 
increasing the expression of BCL-2 and decreasing the 
expressions of p53 and p21, may play an important role 
in oncogenic function of miR-506 in T-ALL. 
 
Conclusion 
In conclusion, overexpression of miR-506 in Jurkat 
cell lines can promote cell viability via increasing BCL-
2 expression. Furthermore, it can reduce cell apoptosis 
by lowering the expression of p53 and p21. Thus, our 
findings revealed the significant roles of miR-506 in T-
ALL pathogenesis, and in consequence, prompting us 
to consider the therapeutics role of miRNAs against 
cancer. Last, additional studies are required to clarify 
the exact interaction mechanism between miRNAs and 
the p53 pathway. 
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